Status:

NOT_YET_RECRUITING

Study on the Relative Dose Intensity of PARP Inhibitors in Real-life on a Population of Patients Over 70 Years With Advanced Ovarian Cancer

Lead Sponsor:

Hospices Civils de Lyon

Conditions:

Ovarian Cancer

Eligibility:

FEMALE

70+ years

Brief Summary

Poly(ADP-ribose) polymerase (PARP) inhibitors are anti-cancer treatments that induce preferential tumor cell death. Their efficacy has been demonstrated in many tumor models, primarily in advanced ova...

Eligibility Criteria

Inclusion

  • Age ≥ 70 years
  • Histologically or cytologically confirmed diagnosis of advanced ovarian cancer (FIGO stage III or IV)
  • PARP inhibitors -naive patient who need to initiate maintenance treatment with PARP inhibitors for the first time (according the the marketing authorization)
  • Patient with a life expectancy of more then 3 months
  • Informed patient which does not oppose to participate to the study

Exclusion

  • Prior treatment with PARP inhibitors
  • Patient incapable to take oral tablets/capsules
  • Participation in a drug trial that does not authorize concurrent participation in another trials
  • Person unable to attend scheduled examinations/appointments as part of routine care for geographical, social or psychological reasons
  • Concomitant cancer or f cancer history (other than those included in the inclusion criteria) treated and considered cured for less than 2 years. However, patients with the following pathologies are eligible:
  • Basal cell carcinoma or non-invasive cutaneous squamous cell carcinoma
  • Stage 1B or less cervical carcinoma
  • Non-invasive superficial bladder cancer

Key Trial Info

Start Date :

November 1 2024

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

May 1 2026

Estimated Enrollment :

50 Patients enrolled

Trial Details

Trial ID

NCT06572735

Start Date

November 1 2024

End Date

May 1 2026

Last Update

August 27 2024

Active Locations (9)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (9 locations)

1

Centre Hospitalier Universitaire d'Amiens Picardie Site Sud

Amiens, France, 80054

2

Centre de lutte contre le cancer Jean Perrin

Clermont-Ferrand, France, 63011

3

Groupe Hospitalier Public Sud de l'Oise

Creil, France, 60100

4

Centre Georges François Leclerc

Dijon, France, 21079

Study on the Relative Dose Intensity of PARP Inhibitors in Real-life on a Population of Patients Over 70 Years With Advanced Ovarian Cancer | DecenTrialz